

Radwan Massoud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2048058/publications.pdf>

Version: 2024-02-01

41
papers

407
citations

932766

10
h-index

794141

19
g-index

41
all docs

41
docs citations

41
times ranked

812
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 1548-1555.	1.3	3
2	Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection. Bone Marrow Transplantation, 2021, 56, 1478-1481.	1.3	9
3	A Pin1/PML/P53 axis activated by retinoic acid in <i>NPM-1c</i> acute myeloid leukemia. Haematologica, 2021, 106, 3090-3099.	1.7	11
4	Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients. Leukemia Research, 2021, 105, 106568.	0.4	3
5	Enhanced Immune Reconstitution of T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia. Transplantation and Cellular Therapy, 2021, 27, 841-850.	0.6	13
6	Haploidentical related donor allogeneic hematopoietic stem cell transplantation for patient aged older than 76 years with refractory acute myeloid leukemia. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 175-177.	0.6	1
7	Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 371-376.e1.	0.2	2
8	Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 617-623.	0.2	23
9	Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 1732-1735.	0.6	5
10	The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study. Current Research in Translational Medicine, 2020, 68, 51-58.	1.2	1
11	Assessment of Caries Index and Fluoride Intake in a Pediatric Middle Eastern Population. Journal of Contemporary Dental Practice, 2020, 21, 1098-1104.	0.2	0
12	Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. Nature Communications, 2019, 10, 2891.	5.8	36
13	Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 506-508.	0.2	36
14	S117 THE ROLE OF ANTI-THYMOCYTE GLOBULIN WITH THIOTEPA-BUSULFAN-FLUDARABINE BASED CONDITIONING IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANT AND POST-TRANSPLANT CYCLOPHOSPHAMIDE. HemaSphere, 2019, 3, 10-11.	1.2	0
15	Site specific diagnostic yield of endoscopic biopsies in Gastrointestinal Graft-versus-Host Disease: A tertiary care Center experience. Current Research in Translational Medicine, 2019, 67, 16-19.	1.2	9
16	Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 620-624.	1.3	14
17	Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 368-374.	0.2	3
18	Real Life Experience with Plerixafor and Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S311.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patient Aged over 76 Years with Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S196-S197.	0.2	0
20	Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e441-e444.	0.2	19
21	Mutations in Human Histone H3 are Pre-Leukemic Events and Promote Hematopoietic Stem Cell Expansion and Leukemic Aggressiveness. <i>Experimental Hematology</i> , 2018, 64, S55-S56.	0.2	0
22	Role of 2677G>>T>>A Genetic Polymorphism in the ABCB1 Drug Transporter in the Interaction between Voriconazole and Cyclosporine and Cyclosporine Related Nephrotoxicity After Allogeneic Stem Cell Transplantation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-6-6.	0.0	0
23	Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial. <i>Blood</i> , 2018, 132, 5445-5445.	0.6	0
24	Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1074-1077.	1.3	38
25	Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2017, 52, 918-921.	1.3	32
26	Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 2867-2874.	2.0	100
27	Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 2745-2747.	0.6	3
28	Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Virology</i> , 2017, 95, 36-41.	1.6	10
29	Trends in hematopoietic stem cell transplant activity in Lebanon. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 315-320.	0.6	8
30	Progressive multifocal leukoencephalopathy in patients receiving rituximab and cyclophosphamide after haplo-identical T-cell replete transplantation and review of the literature. <i>Current Research in Translational Medicine</i> , 2017, 65, 127-132.	1.2	1
31	Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 179-185.	0.2	19
32	Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2017, 52, 1187-1190.	1.3	4
33	Post Transplant Brentuximab Maintenance Appears more Effective than Post Transplant Salvage Brentuximab for Relapsed /Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S68.	0.2	0
34	Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: a Single-Center Study at the American University of Beirut Medical Center (AUBMC). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S122-S123.	0.2	0
35	Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S34-S35.	0.2	0
36	Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4624-4624.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Post Transplant Brentuximab Maintenance Appears More Effective Than Post Transplant Salvage Brentuximab for Relapsed/Refractory Hodgkin's Lymphoma. Blood, 2016, 128, 5357-5357.	0.6	1
38	Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML. Blood, 2016, 128, 5872-5872.	0.6	1
39	Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC). Blood, 2016, 128, 5824-5824.	0.6	0
40	Bendamustine Demonstrates Promising Activity in Post-Brentuximab Failure Hodgkin Lymphoma Patients Who Had Also Failed a Prior Autologous HCT and Facilitates Successful Bridging to Allogeneic HCT. Blood, 2016, 128, 5359-5359.	0.6	0
41	Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant. Blood, 2016, 128, 5238-5238.	0.6	0